Recently, Bristol-Myers Squibb Co. (BMY) received approval from the U.S. Food and Drug Administration (FDA) to market Abilify (aripiprazole) for the treatment of irritability in pediatric patients having autistic disorder. Abilify can be used to treat children aged 6 to 17 years for symptoms of aggression toward others, deliberate self injury, temper tantrums and quick mood swings.  Bristol-Myers and Otsuka Pharmaceutical Co. jointly develop and distribute the drug in the U.S. and Europe. The FDA approval of Abilify for treating irritation in pediatric patients with autistic disorder is based on data from two eight-week late-stage studies in which Abilify significantly improved scores on the irritability subscale of the caregiver-rated Aberrant Behavior Checklist (ABC-I), compared to placebo.  The most common adverse affects were sedation, fatigue, vomiting, somnolence, tremor and pyrexia. However, the efficacy of Abilify for the maintenance treatment of irritability associated with autistic disorder was not ...

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

American Superconductor Corp (AMSC) AstraZeneca Plc (AZN) Balchem Corp (BCPC) Banco de Chile (BCH) RG Barry Corp (DFZ) Bio-Rad Laboratories Inc (BIO) CareFusion Corp (CFN) Chico's FAS Inc (CHS) China Green Agriculture Inc (CGA) Clearwater Paper Corp (CLW) CNinsure Inc (CISG) Conexant Systems Inc (CNXT) Corinthian Colleges Inc (COCO) Fossil Inc (FOSL) Genoptix Inc (GXDX) HSN Inc (HSNI) Information Services Group Inc (III) Keynote ...

Baxter International Inc. (BAX) announced that it sees multiyear opportunity in H1N1 vaccines, commonly known as Swine Flu vaccines. The company expects to recognize $30 million to $40 million in revenues from swine flu vaccines in the fourth quarter. Baxter has not speculated on H1N1 vaccine sales beyond the fourth quarter. However, increasing demand has raised hopes for a multiyear opportunity. Baxter started shipping the product from August 2009.   Baxter and four other companies Sanofi-Aventis (SNY); MedImmune, a subsidiary of AstraZeneca plc (AZN); GlaxoSmithKline plc (GSK); and Novartis have received authorization to market H1N1 vaccines. Baxter has received approval only for a two-dose vaccine and not a single-dose. Baxter uses its cell culture-based technology instead of the traditional one to produce these vaccines.   Baxter recently announced strong third quarter results. Earnings per share stood at 98 cents, surpassing the Zacks Consensus Estimate of ...

For Immediate Release

Chicago, IL – October 7, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Bristol-Myers Squibb Co. (BMY), AstraZeneca Plc (AZN), Merck & Co (MRK), GlaxoSmithKline (GSK) and Eli Lilly (LLY).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday’s Analyst Blog:

European Nod for Bristol Drug

Yesterday, Bristol-Myers Squibb Co. (BMY) and AstraZeneca Plc (AZN) announced that their diabetes drug Onglyza (saxagliptin) received the green light from the European Commission to be marketed in the 27 countries of the European Union (EU). Onglyza once daily

...

Yesterday, Bristol-Myers Squibb Co. (BMY) and AstraZeneca Plc (AZN) announced that their diabetes drug Onglyza (saxagliptin) received the green light from the European Commission to be marketed in the 27 countries of the European Union (EU). Onglyza once daily was co-developed by Bristol-Myers and AstraZeneca. Onglyza can be used in combination with commonly prescribed oral anti-diabetic medications − metformin, sulfonylureas or thiazolidinediones for improving blood sugar levels in adults when those drugs alone fail to adequately control glycemic levels. The European approval is based on data from late-stage registrational trials which assessed the safety and efficacy of the drug and involved 4,148 type-II diabetes patients, including 3,021 patients treated with Onglyza. Onglyza is expected to be launched in Europe in the fourth quarter of this year. It will be the first diabetes drug to be launched in Europe under this partnership. As a reminder, ...

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

3M Co (MMM) AeroCentury Corp (ACY) American Italian Pasta Co (AIPC) America's Car-Mart Inc (CRMT) Assisted Living Concepts Inc (ALC) AstraZeneca Plc (AZN) Barnes & Noble Inc (BKS) The Boston Beer Co (SAM) Cardtronics Inc (CATM) Cellcom Israel Ltd (CEL) Chico's FAS Inc (CHS) China Petroleum & Chemical Corp (SNP) Cymer Inc (CYMI) Deluxe Corp (DLX) Dr Pepper Snapple Group Inc (DPS) Emergency Medical Services Corp (EMS) Evercore ...

 

PennyOmega.com Hot Stock News & Alerts!

________________________________________

FREE Daily Stock Alerts From PennyOmega.com

________________________________________

 

Monday August 31, 2009

PennyOmega.com Stock Report!

**************************************************************

AZN, AstraZeneca plc

A new drug to prevent blood clots in heart patients reduced their chances of dying by more than 20 percent compared with the standard treatment, new research says.

AZN is ready to launch a challenge to the world’s second-best selling drug.

Tests of AZN’s new

...

Last week, Array BioPharma Inc. (ARRY) reported a fourth-quarter net loss of 55 cents per share which was in line with the Zacks Consensus Estimate. The company had a loss of 68 cents in the year-ago quarter. Net loss for fiscal 2009 was $2.67 per share, compared with $2.04 last year.

Quarterly revenue came in at $5.5 million, representing a 10% decline from the comparable quarter in 2008. Sales for the full year fell by 13% to $25 million.

The narrower quarterly loss was primarily attributable to lower spending on research and development. The company spent $21.3 million towards research and development for the quarter for the clinical advancement of its wholly owned drugs versus $28.4 million in year-ago quarter.

Last January, Array had announced a restructuring plan of scaling down its research and development costs and accelerating partnership initiatives to ensure sustainable growth under current market conditions.

...

For Immediate Release

Chicago, IL – August 4, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Bristol-Myers Squibb Co. (BMY), AstraZeneca Plc (AXN), Merck (MRK), Novartis (NVS) and Medarex (MEDX).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Monday’s Analyst Blog:

FDA Approves Bristol’s Diabetes Drug

We are pleased with the FDA’s approval of Bristol-Myers Squibb Co.’s (BMY) diabetes drug Onglyza that the company distributes with AstraZeneca Plc (AXN). The drug regulates blood-sugar levels in Type 2 diabetes that affects about 24 million people in the U.S.

...

BMY, Bristol-Myers Squibb Co.

AZN, AstraZeneca plc

FNXC, Fonix Corp, FNXC.OB

DrStockPick Watch List!

 

DrStockPick Watch List! for Monday August 3, 2009

 

My Picks for Monday August 3, 2009 are:

**************************************************************

BMY, Bristol-Myers Squibb Co. and AZN, AstraZeneca plc

BMY is a global biopharmaceutical company whose mission is to extend and enhance human life.

AZN is a major international healthcare business engaged in the research, development, manufacturing and marketing of prescription medicines and supplier for healthcare services. AstraZeneca is one of the world’s leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.

Bristol-Myers Squibb and AstraZeneca entered into a collaboration

...